{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:02:18Z","timestamp":1784962938421,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"DOI":"10.1007\/s10461-026-05256-6","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:49:58Z","timestamp":1784962198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Burden of Sexually Transmitted Infections Among Pre-exposure Prophylaxis (PrEP) Users: Testing and Prevention Needs"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0635-364X","authenticated-orcid":false,"given":"Elia","family":"Asensi-D\u00edaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Barcenilla","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cort\u00e9s","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Mahillo-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mart\u00edn-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"\u00c1lvarez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Carrillo-Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aws","family":"Al-Hayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Prieto-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta L\u00f3pez","family":"de Las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"G\u00f3rgolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Cabello-\u00dabeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"5","key":"5256_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048478","volume":"12","author":"E O Murchu","year":"2022","unstructured":"O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12(5):e048478. https:\/\/doi.org\/10.1136\/bmjopen-2020-048478.","journal-title":"BMJ Open"},{"key":"5256_CR2","volume-title":"Consensus document \u2013 HIV Pre-exposure Prophylaxis in Spain","author":"National AIDS Plan Expert Group on PrEP","year":"2018","unstructured":"National AIDS Plan Expert Group on PrEP. Consensus document \u2013 HIV Pre-exposure Prophylaxis in Spain. Madrid: Ministerio de Sanidad; 2018."},{"issue":"10","key":"5256_CR3","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1093\/cid\/civ778","volume":"61","author":"JE Volk","year":"2015","unstructured":"Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601\u20133. https:\/\/doi.org\/10.1093\/cid\/civ778.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"5256_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eimce.2024.03.004","volume":"42","author":"O Ayerdi","year":"2024","unstructured":"Ayerdi O, Orviz E, Valls Carb\u00f3 A, Fern\u00e1ndez Pi\u00f1eiro N, Vera Garc\u00eda M, Puerta L\u00f3pez T, et al. Incidence of sexually transmitted infections and screening models among pre-exposure prophylaxis users. Enferm Infecc Microbiol Clin. 2024;42(10):570\u20136. https:\/\/doi.org\/10.1016\/j.eimce.2024.03.004.","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"14","key":"5256_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1097\/QAD.0000000000001185","volume":"30","author":"N Kojima","year":"2016","unstructured":"Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men. AIDS. 2016;30(14):2251\u20132. https:\/\/doi.org\/10.1097\/QAD.0000000000001185.","journal-title":"AIDS"},{"issue":"10","key":"5256_CR6","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2352-3018(24)00211-X","volume":"11","author":"MS Torres Silva","year":"2024","unstructured":"Torres Silva MS, Torres TS, Coutinho C, Ism\u00e9rio Moreira R, da Costa Leite I, Cunha M, et al. Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study. Lancet HIV. 2024;11(10):e667-76. https:\/\/doi.org\/10.1016\/S2352-3018(24)00211-X.","journal-title":"Lancet HIV"},{"issue":"1","key":"5256_CR7","doi-asserted-by":"publisher","first-page":"e0245925","DOI":"10.1371\/journal.pone.0245925","volume":"16","author":"O Ayerdi","year":"2021","unstructured":"Ayerdi O, Garc\u00eda V, Arias Ram\u00edrez D, Garc\u00eda NG, L\u00f3pez TP, et al. Low use of condoms and high STI incidence among men who have sex with men in PrEP programs. PLoS ONE. 2021;16(1):e0245925. https:\/\/doi.org\/10.1371\/journal.pone.0245925.","journal-title":"PLoS ONE"},{"key":"5256_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/sextrans-2021-055381","volume":"99","author":"TA Hart","year":"2023","unstructured":"Hart TA, Noor SW, Berlin GW, Skakoon-Sparling S, Tavangar F, Tan D, et al. Pre-exposure prophylaxis and bacterial sexually transmitted infections among gay and bisexual men. Sex Transm Infect. 2023;99:167\u201372. https:\/\/doi.org\/10.1136\/sextrans-2021-055381.","journal-title":"Sex Transm Infect"},{"key":"5256_CR9","volume-title":"SiPrEP 2024 Report","author":"J Del Amo","year":"2024","unstructured":"Del Amo J, D\u00edaz A, Jarr\u00edn I, Hernando V, Cobos M, Nu\u00f1o N. SiPrEP 2024 Report. Madrid: Instituto de Salud Carlos III; 2024."},{"key":"5256_CR10","volume-title":"Diagn\u00f3stico y tratamiento de las infecciones de transmisi\u00f3n sexual en adultos, ni\u00f1os y adolescentes. Documento de consenso","author":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","year":"2026","unstructured":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Diagn\u00f3stico y tratamiento de las infecciones de transmisi\u00f3n sexual en adultos, ni\u00f1os y adolescentes. Documento de consenso. Madrid: SEIMC; 2026."},{"issue":"1","key":"5256_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eimce.2022.06.009","volume":"41","author":"M Laguno","year":"2023","unstructured":"Laguno M, Ugarte A, Mart\u00ednez-Rebollar M, Sobrino Y, Font G, de Lazzari E, et al. PrEP programme experience in a hospital HIV unit: baseline user profile and identification of opportunities for improvement. Enferm Infecc Microbiol Clin. 2023;41(1):24\u20138. https:\/\/doi.org\/10.1016\/j.eimce.2022.06.009.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"5256_CR12","volume-title":"Documento de posicionamiento sobre el uso profil\u00e1ctico de doxiciclina para prevenir las ITS (doxi-PEP)","author":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","year":"2024","unstructured":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, Grupo de Estudio en Infecciones de Transmisi\u00f3n Sexual, Grupo de Estudio del SIDA, Grupo de Estudio de los Mecanismos de Acci\u00f3n y de la Resistencia a los Antimicrobianos. Documento de posicionamiento sobre el uso profil\u00e1ctico de doxiciclina para prevenir las ITS (doxi-PEP). Madrid: SEIMC; 2024."},{"issue":"3","key":"5256_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.eimce.2024.06.001","volume":"43","author":"N Fern\u00e1ndez Pi\u00f1eiro","year":"2025","unstructured":"Fern\u00e1ndez Pi\u00f1eiro N, Ayerdi Aguirrebengoa O, Orviz Garc\u00eda E, Gonz\u00e1lez P\u00e9rez C, Vera Garc\u00eda M, Puerta L\u00f3pez T, et al. Pre-exposure prophylaxis program in the Community of Madrid: two years of experience. Enferm Infecc Microbiol Clin. 2025;43(3):133\u20138. https:\/\/doi.org\/10.1016\/j.eimce.2024.06.001.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"5256_CR14","doi-asserted-by":"publisher","first-page":"e067261","DOI":"10.1136\/bmjopen-2022-067261","volume":"12","author":"S Nozza","year":"2022","unstructured":"Nozza S, Raccagni AR, Lolatto R, Ceccarelli D, Galli L, Alberton F, et al. Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort. BMJ Open. 2022;12:e067261. https:\/\/doi.org\/10.1136\/bmjopen-2022-067261.","journal-title":"BMJ Open"},{"issue":"8","key":"5256_CR15","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.1016\/S2352-3018(22)00133-3","volume":"9","author":"JM Molina","year":"2022","unstructured":"Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS Pr\u00e9venir): a prospective observational cohort study. Lancet HIV. 2022;9(8):e554\u201362.","journal-title":"Lancet HIV"},{"key":"5256_CR16","volume-title":"Vigilancia epidemiol\u00f3gica del VIH y SIDA en Espa\u00f1a 2023","author":"Ministerio de Sanidad","year":"2023","unstructured":"Ministerio de Sanidad. Vigilancia epidemiol\u00f3gica del VIH y SIDA en Espa\u00f1a 2023. Madrid: Direcci\u00f3n General de Salud P\u00fablica y Equidad en Salud; 2023."},{"issue":"3","key":"5256_CR17","doi-asserted-by":"publisher","first-page":"e25005","DOI":"10.1002\/jia2.25105","volume":"21","author":"E Hoornenborg","year":"2018","unstructured":"Hoornenborg E, Achterbergh RCA, van der Loeff MFS, Davidovich U, van der Helm JJ, Hogewoning A, et al. Men who have sex with men more often choose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam. J Int AIDS Soc. 2018;21(3):e25005. https:\/\/doi.org\/10.1002\/jia2.25105.","journal-title":"J Int AIDS Soc"},{"issue":"15","key":"5256_CR18","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1097\/QAD.0000000000001939","volume":"32","author":"M Noret","year":"2018","unstructured":"Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, et al. Daily or on-demand oral tenofovir disoproxil fumarate\/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. AIDS. 2018;32(15):2161\u20139. https:\/\/doi.org\/10.1097\/QAD.0000000000001939.","journal-title":"AIDS"},{"issue":"8","key":"5256_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1177\/09564624251333489","volume":"36","author":"EP Davies","year":"2025","unstructured":"Davies EP, Tsuboi M, Evans J, Rowley J, Korenromp EL, Clayton T, et al. A global meta-analysis of gonorrhoea and chlamydia prevalence among men who have sex with men from 2000 to 2022. Int J STD AIDS. 2025;36(8):611\u201321. https:\/\/doi.org\/10.1177\/09564624251333489.","journal-title":"Int J STD AIDS"},{"issue":"3","key":"5256_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/sextrans-2024-056276","volume":"101","author":"B Teker","year":"2025","unstructured":"Teker B, Schim van der Loeff MF, Boyd A, Hoornenborg E, Stam AJ, de Vries HJC, et al. Increase in Neisseria gonorrhoeae infections after ending COVID-19 lockdown measures in Amsterdam, the Netherlands. Sex Transm Infect. 2025;101(3):152\u20139. https:\/\/doi.org\/10.1136\/sextrans-2024-056276.","journal-title":"Sex Transm Infect"},{"key":"5256_CR21","doi-asserted-by":"publisher","first-page":"101318","DOI":"10.1016\/j.lanepe.2025.101318","volume":"54","author":"S Jacobsson","year":"2025","unstructured":"Jacobsson S, Cole MJ, Schr\u00f6der D, van Jansen M, Day M, K\u00f6dm\u00f6n C, et al. Antimicrobial resistance in Neisseria gonorrhoeae and its risk groups in 23 European countries in 2022: results from Euro-GASP. Lancet Reg Health Eur. 2025;54:101318. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101318.","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"5256_CR22","doi-asserted-by":"publisher","first-page":"e2127","DOI":"10.1093\/cid\/ciaa1832","volume":"73","author":"B Ber\u00e7ot","year":"2021","unstructured":"Ber\u00e7ot B, Charreau I, Rousseau C, Delaugerre C, Chidiac C, Pialoux G, et al. High prevalence and antibiotic resistance of Mycoplasma genitalium infections in men who have sex with men: a substudy of the ANRS IPERGAY trial. Clin Infect Dis. 2021;73(7):e2127\u201333. https:\/\/doi.org\/10.1093\/cid\/ciaa1832.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"5256_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.101047","volume":"6","author":"TP Chua","year":"2025","unstructured":"Chua TP, Vodstrcil LA, Murray GL, Plummer EL, Jensen JS, Unemo M, et al. Evolving patterns of macrolide and fluoroquinolone resistance in Mycoplasma genitalium: an updated systematic review and meta-analysis. Lancet Microbe. 2025;6(7):101047. https:\/\/doi.org\/10.1016\/j.lanmic.2024.101047.","journal-title":"Lancet Microbe"},{"issue":"12","key":"5256_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/OLQ.0000000000001493","volume":"48","author":"H Fifer","year":"2021","unstructured":"Fifer H, Merrick R, Pitt R, Yung M, Allen H, Day M, et al. Frequency and correlates of Mycoplasma genitalium antimicrobial resistance mutations and their association with treatment outcomes: findings from a national sentinel surveillance pilot in England. Sex Transm Dis. 2021;48(12):951\u20134. https:\/\/doi.org\/10.1097\/OLQ.0000000000001493.","journal-title":"Sex Transm Dis"},{"issue":"7","key":"5256_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/sextrans-2023-056044","volume":"100","author":"C Bjartling","year":"2024","unstructured":"Bjartling C, Kertes R, Kristiansen S, Johnsson A, Forslund O. Prevalence of Mycoplasma genitalium and macrolide resistance in rectal and urine samples among men who have sex with men in Sweden. Sex Transm Infect. 2024;100(7):430\u20134. https:\/\/doi.org\/10.1136\/sextrans-2023-056044.","journal-title":"Sex Transm Infect"},{"issue":"4","key":"5256_CR26","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3201\/eid2504.181258","volume":"25","author":"TRH Read","year":"2019","unstructured":"Read TRH, Murray GL, Danielewski J, Fairley CK, Doyle M, Chow EPF, et al. Symptoms, sites, and significance of Mycoplasma genitalium in men who have sex with men. Emerg Infect Dis. 2019;25(4):719\u201327. https:\/\/doi.org\/10.3201\/eid2504.181258.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"5256_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cmi.2015.11.016","volume":"22","author":"M Bissessor","year":"2016","unstructured":"Bissessor M, Fairley CK, Tabrizi SN, Bradshaw CS, Twin J, Chen MY, et al. The contribution of Mycoplasma genitalium to the aetiology of sexually acquired infectious proctitis in men who have sex with men. Clin Microbiol Infect. 2016;22(3):260\u20135. https:\/\/doi.org\/10.1016\/j.cmi.2015.11.016.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"5256_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1\u2013187. https:\/\/doi.org\/10.15585\/mmwr.rr7004a1.","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"5256_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.mcna.2023.07.004","volume":"108","author":"OA Obafemi","year":"2024","unstructured":"Obafemi OA, Mehta SD, Jensen JS, Manhart LE, Gaydos CA, Taylor SN, et al. Mycoplasma genitalium: key information for the primary care clinician. Med Clin North Am. 2024;108(2):297\u2013310. https:\/\/doi.org\/10.1016\/j.mcna.2023.07.004.","journal-title":"Med Clin North Am"},{"issue":"14","key":"5256_CR30","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","volume":"388","author":"AF Luetkemeyer","year":"2023","unstructured":"Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388(14):1296\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa2211934.","journal-title":"N Engl J Med"},{"issue":"12","key":"5256_CR31","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1097\/QAD.0000000000004233","volume":"39","author":"E Rubenstein","year":"2025","unstructured":"Rubenstein E, Molina JM. Doxycycline to prevent bacterial sexually transmitted infections: a promising intervention. AIDS. 2025;39(12):1677\u201387. https:\/\/doi.org\/10.1097\/QAD.0000000000004233.","journal-title":"AIDS"},{"key":"5256_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107186","volume":"147","author":"I Szondy","year":"2024","unstructured":"Szondy I, Meznerics FA, L\u0151rincz K, Kem\u00e9ny LV, Walter A, Mohammed AA, et al. Doxycycline prophylaxis for the prevention of sexually transmitted infections: a systematic review and meta-analysis of randomised controlled trials. Int J Infect Dis. 2024;147:107186. https:\/\/doi.org\/10.1016\/j.ijid.2024.107186.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"5256_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/sextrans-2024-056208","volume":"101","author":"PR Sokoll","year":"2025","unstructured":"Sokoll PR, Migliavaca CB, D\u00f6ring S, Traub U, Stark K, Sardeli AV, et al. Efficacy of postexposure prophylaxis with doxycycline (Doxy-PEP) in reducing sexually transmitted infections: a systematic review and meta-analysis. Sex Transm Infect. 2025;101(1):59\u201367. https:\/\/doi.org\/10.1136\/sextrans-2024-056208.","journal-title":"Sex Transm Infect"},{"issue":"6","key":"5256_CR34","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/cid\/ciaf089","volume":"80","author":"OO Soge","year":"2025","unstructured":"Soge OO, Thibault CS, Cannon CA, McLaughlin SE, Menza TW, Dombrowski JC, et al. Potential impact of doxycycline postexposure prophylaxis on tetracycline resistance in Neisseria gonorrhoeae and colonization with tetracycline-resistant Staphylococcus aureus and Group A Streptococcus. Clin Infect Dis. 2025;80(6):1188\u201396. https:\/\/doi.org\/10.1093\/cid\/ciaf089.","journal-title":"Clin Infect Dis"},{"issue":"28","key":"5256_CR35","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1016\/j.vaccine.2020.02.073","volume":"38","author":"SL Gottlieb","year":"2020","unstructured":"Gottlieb SL, Ndowa F, Hook EW, Deal C, Chow EPF, Jerse AE, et al. Gonococcal vaccines: public health value and preferred product characteristics. Vaccine. 2020;38(28):4362\u201373. https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.073.","journal-title":"Vaccine"},{"key":"5256_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02417","volume":"10","author":"MW Russell","year":"2019","unstructured":"Russell MW, Jerse AE, Gray-Owen SD. Progress toward a gonococcal vaccine: the way forward. Front Immunol. 2019;10:2417. https:\/\/doi.org\/10.3389\/fimmu.2019.02417.","journal-title":"Front Immunol"},{"issue":"19 Suppl 1","key":"5256_CR37","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.vaccine.2023.01.053","volume":"42","author":"Y Lyu","year":"2024","unstructured":"Lyu Y, Choong A, Chow EPF, Fairley CK, Ong JJ, Lewis DA, et al. Vaccine value profile for Neisseria gonorrhoeae. Vaccine. 2024;42(19 Suppl 1):S42\u201369. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.053.","journal-title":"Vaccine"},{"issue":"3","key":"5256_CR38","doi-asserted-by":"publisher","first-page":"e1341","DOI":"10.1093\/cid\/ciac436","volume":"76","author":"KJ Bruxvoort","year":"2023","unstructured":"Bruxvoort KJ, Lewnard JA, Chen LH, Jung J, Ackerson BK, Florea A, et al. Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in Southern California. Clin Infect Dis. 2023;76(3):e1341\u20139. https:\/\/doi.org\/10.1093\/cid\/ciac436.","journal-title":"Clin Infect Dis"},{"issue":"26","key":"5256_CR39","doi-asserted-by":"publisher","first-page":"126416","DOI":"10.1016\/j.vaccine.2024.126416","volume":"42","author":"S Taha","year":"2024","unstructured":"Taha S, Eskandari S, Slesarenko VA, Gulati S, Zhu W, Ram S, et al. Refinement and optimisation of Neisseria gonorrhoeae NHBA and MetQ vaccine candidates. Vaccine. 2024;42(26):126416. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126416.","journal-title":"Vaccine"},{"key":"5256_CR40","doi-asserted-by":"publisher","first-page":"1688536","DOI":"10.3389\/fimmu.2025.1688536","volume":"16","author":"SK Roe","year":"2025","unstructured":"Roe SK, Zheng B, Gulati S, Kopp A, Jerse AE, Rice PA, et al. Preclinical in vivo evaluation of a gonococcal multivalent vaccine containing antigens identified by CASS. Front Immunol. 2025;16:1688536. https:\/\/doi.org\/10.3389\/fimmu.2025.1688536.","journal-title":"Front Immunol"},{"issue":"5","key":"5256_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/QAI.0000000000002186","volume":"82","author":"P Van Epps","year":"2019","unstructured":"Van Epps P, Wilson BM, Garner W, Beste LA, Maier MM, Ohl ME, et al. Brief report: incidence of HIV in a nationwide cohort receiving pre-exposure prophylaxis for HIV prevention. J Acquir Immune Defic Syndr. 2019;82(5):427\u201330. https:\/\/doi.org\/10.1097\/QAI.0000000000002186.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"5256_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/apc.2017.0263","volume":"32","author":"A Gonz\u00e1lez-Baeza","year":"2018","unstructured":"Gonz\u00e1lez-Baeza A, Dolengevich-Segal H, P\u00e9rez-Valero I, Cabello A, T\u00e9llez MJ, Dronda F, et al. Sexualized drug use (chemsex) is associated with high-risk sexual behaviours and sexually transmitted infections in HIV-positive MSM: data from the U-SEX GESIDA 9416 study. AIDS Patient Care STDs. 2018;32(3):112\u20138. https:\/\/doi.org\/10.1089\/apc.2017.0263.","journal-title":"AIDS Patient Care STDs"},{"issue":"3","key":"5256_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s13178-022-00702-1","volume":"20","author":"L De la Mora","year":"2023","unstructured":"De la Mora L, \u00c1lvarez del Arco D, Guill\u00e9n-Gonz\u00e1lez MJ, Poveda-G\u00f3mez F, Garc\u00eda-G\u00f3mez R, Gonz\u00e1lez-Garc\u00eda J, et al. Vulnerability conditions in a cohort of men who have sex with men who engage in chemsex in Barcelona City: a cross-sectional study. Sex Res Soc Policy. 2023;20(3):614\u201325. https:\/\/doi.org\/10.1007\/s13178-022-00702-1.","journal-title":"Sex Res Soc Policy"},{"key":"5256_CR44","volume-title":"Community Report 1: Key findings on mental health and chemsex","author":"EMIS-2024 (European MSM Internet Survey)","year":"2024","unstructured":"EMIS-2024 (European MSM Internet Survey). Community Report 1: Key findings on mental health and chemsex. Berlin: Robert Koch Institute; 2024."},{"issue":"1","key":"5256_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.22206\/cysa.2024.v8i2.2893","volume":"18","author":"R V\u00e1zquez-G\u00f3mez","year":"2024","unstructured":"V\u00e1zquez-G\u00f3mez R, V\u00e1zquez-G\u00f3mez M. Pre-exposure prophylaxis of HIV in men who have sex with men and its influence on other sexually transmitted infections: a bibliographic review. Ciencia y Salud. 2024;18(1):42\u201357. https:\/\/doi.org\/10.22206\/cysa.2024.v8i2.2893.","journal-title":"Ciencia y Salud"},{"key":"5256_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.drugpo.2018.11.014","volume":"63","author":"S Maxwell","year":"2019","unstructured":"Maxwell S, Shahmanesh M, Gafos M. Chemsex behaviours among men who have sex with men: a systematic review of the literature. Int J Drug Policy. 2019;63:74\u201389. https:\/\/doi.org\/10.1016\/j.drugpo.2018.11.014.","journal-title":"Int J Drug Policy"},{"key":"5256_CR47","volume-title":"The Chemsex Study: Drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham","author":"A Bourne","year":"2014","unstructured":"Bourne A, Reid D, Hickson F, Torres Rueda S, Weatherburn P. The Chemsex Study: Drug use in sexual settings among gay and bisexual men in Lambeth, Southwark and Lewisham. London: Sigma Research, London School of Hygiene & Tropical Medicine; 2014. https:\/\/researchonline.lshtm.ac.uk\/id\/eprint\/2197245\/."},{"issue":"10","key":"5256_CR48","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1007\/s10461-023-04041-z","volume":"27","author":"DJ Field","year":"2023","unstructured":"Field DJ, de Wit J, Davoren MP, O\u2019Reilly EJ, Den Daas C. Chemsex, anxiety and depression among gay, bisexual and other men who have sex with men living with HIV. AIDS Behav. 2023;27(10):3206\u201312. https:\/\/doi.org\/10.1007\/s10461-023-04041-z.","journal-title":"AIDS Behav"},{"key":"5256_CR49","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Rebollar M, De la Mora L, Campistol M, Cabrera B, Bagu\u00e9 A, De Lazzari E et al. Impact of sexualized substance use and other risk practices on HCV microelimination in gbMSM living with HIV: urgent need for targeted strategies. Results of a retrospective cohort study. Infect Dis Ther. 2021; 10(3):1253\u201366. https:\/\/doi.org\/10.1007\/s40121-021-00448-0.","DOI":"10.1007\/s40121-021-00448-0"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-026-05256-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-026-05256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:50:00Z","timestamp":1784962200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-026-05256-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":49,"alternative-id":["5256"],"URL":"https:\/\/doi.org\/10.1007\/s10461-026-05256-6","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"10 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following conflict of interest, financial or otherwise: ACU reports grants and personal fees from ViiV Healthcare and Gilead Sciences, personal fees from Johnson & Johnson and Merck, unrelated to the submitted work. MG reports personal fees from ViiV Healthcare, Gilead Sciences and Johnson & Johnson, unrelated to the submitted work. BA reports grants and personal fees from Gilead and personal fees from ViiV Healthcare, unrelated to the submitted work. AAH reports personal fees from ViiV Healthcare, Gilead, Johnson & Johnson, and Merck, unrelated to the submitted work. IC reports personal fees from ViiV Healthcare, Gilead, Johnson & Johnson, and Merck, unrelated to the submitted work. Other authors have no conflicts of interest.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A waiver of informed consent was granted from the Ethics Committee. All collected data were anonymized. Approval was obtained from the Institutional Research Ethics Committee (Approval no. TFG 106-24 from the Fundaci\u00f3n Jim\u00e9nez D\u00edaz Medical University Hospital Ethics Committee, Community of Madrid, Spain). All research was performed in accordance with the General Data Protection Regulation (GDPR) (Regulation (EU) 2016\/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons regarding the processing of personal data (General Data Protection Regulation) and the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}